Neuroendocrine bladder cancer is extremely rare, with an estimated incidence of 0.5%- 0.7%. In bladder cancers there is no evident connection between the neuroendocrine phenotypic expression and the clinical history. However, prognosis is usually poor and the survival rate at 5 years does not exceed 8%, if untreated. METHODS. We are here describing three case reports of bladder carcinoma with neuroendocrine differentiation, which is extremely aggressive and leads rapidly to death. At the present time, the local control of these tumors is achieved by radical cystectomy and radiotherapy; they can be both associated to chemotherapy. However, since these lesions are fairly rare, there is no gold standard therapy and there are no prospective stu...
Primary small cell neuro-endocrine carcinoma is rare malignancy in urinary bladder. We report a case...
Purpose: Small cell neuroendocrine bladder carcinoma is a rare entity, account for less than 1% of a...
There is scant evidence about optimal management of poorly differentiated neuroendocrine carcinoma o...
Neuroendocrine bladder cancer is extremely rare, with an estimated incidence of 0.5%- 0.7%. In bladd...
Neuroendocrine tumors rarely occur in the urinary bladder. They can be carcinomatous, subdivided int...
Neuroendocrine tumors rarely occur in the urinary bladder, relatively less than 1% of occurrence, as...
Neuroendocrine tumors rarely occur in the urinary bladder, relatively less than 1% of occurrence, as...
OBJECTIVE: Neuroendocrine bladder tumours are rare entities known for their aggressive behaviour....
BACKGROUND: Neuroendocrine tumors (NET) are uncommon neoplasms. Small cell carcinoma of the bladder ...
OBJECTIVE: Neuroendocrine bladder tumours are rare entities known for their aggressive behaviour. Th...
OBJECTIVE: Neuroendocrine bladder tumours are rare entities known for their aggressive behaviour. Th...
The neuoroendocrine cancer of the bladder is a rare tumour, and from this entity the well-differenti...
The neuoroendocrine cancer of the bladder is a rare tumour, and from this entity the well-differenti...
The neuoroendocrine cancer of the bladder is a rare tumour, and from this entity the well-differenti...
BACKGROUND: Small cell carcinoma of the urinary bladder is a rare and aggressive form of bladder can...
Primary small cell neuro-endocrine carcinoma is rare malignancy in urinary bladder. We report a case...
Purpose: Small cell neuroendocrine bladder carcinoma is a rare entity, account for less than 1% of a...
There is scant evidence about optimal management of poorly differentiated neuroendocrine carcinoma o...
Neuroendocrine bladder cancer is extremely rare, with an estimated incidence of 0.5%- 0.7%. In bladd...
Neuroendocrine tumors rarely occur in the urinary bladder. They can be carcinomatous, subdivided int...
Neuroendocrine tumors rarely occur in the urinary bladder, relatively less than 1% of occurrence, as...
Neuroendocrine tumors rarely occur in the urinary bladder, relatively less than 1% of occurrence, as...
OBJECTIVE: Neuroendocrine bladder tumours are rare entities known for their aggressive behaviour....
BACKGROUND: Neuroendocrine tumors (NET) are uncommon neoplasms. Small cell carcinoma of the bladder ...
OBJECTIVE: Neuroendocrine bladder tumours are rare entities known for their aggressive behaviour. Th...
OBJECTIVE: Neuroendocrine bladder tumours are rare entities known for their aggressive behaviour. Th...
The neuoroendocrine cancer of the bladder is a rare tumour, and from this entity the well-differenti...
The neuoroendocrine cancer of the bladder is a rare tumour, and from this entity the well-differenti...
The neuoroendocrine cancer of the bladder is a rare tumour, and from this entity the well-differenti...
BACKGROUND: Small cell carcinoma of the urinary bladder is a rare and aggressive form of bladder can...
Primary small cell neuro-endocrine carcinoma is rare malignancy in urinary bladder. We report a case...
Purpose: Small cell neuroendocrine bladder carcinoma is a rare entity, account for less than 1% of a...
There is scant evidence about optimal management of poorly differentiated neuroendocrine carcinoma o...